



**I-MOVE
13th annual meeting**

**Virtual sessions between
16 and 30 September 2020**

Draft agenda

Quick overview

Approximate Time (CEST)	16th Sept (Wednesday)	18th Sept (Friday)	28th Sept (Monday)	29th Sept (Tuesday)	30th Sept (Wednesday)
9:00-10:20			Session III: Influenza and COVID-19 co-circulation – experience from the Southern Hemisphere and subtropical climates		
14:00-16:45	Session I: 2019–20 influenza VE results from (10)(2a) studies		Session IV: Influenza and COVID-19 co-circulation: challenges and plans at primary care level for (10)(2a) and beyond	Session V: Influenza and COVID-19 co-circulation: challenges and plans at hospital level for (10)(2a) and beyond	Session VII + VIII: Laboratory challenges + Influenza brand/type-specific studies
16:00-18:30		Session II: (10)(2a) 2019–20 influenza VE studies and approaches to COVID-19 surveillance		Session VI: Influenza vaccine and COVID-19	

Alternative time zones¹:

	9:00-10:20 CEST	14:00-16:45 CEST	16:00-18:30 CEST
WEST ((10)(2a) (10)(2a) (10)(2a) time)	8.00-9.30	13.00-15.45	15.00-17.30
EEST ((10)(2a) (10)(2a) time)	10.00-11.30	15.00-17.45	17.00-19.30
(10)(2a)	15.00-16.30	20.00-22.45	22.00-00.30 (+1)
(10)(2a)	18.00-19.30	23.00-25.30	1.00 (+1)-3.30 (+1)
(10)(2a)	1.00-2.30	6.00-8.45	8.00-10.30
(10)(2a)	3.00-4.30	8.00-10.45	10.00-12.30
(10)(2a) (10)(2a) (10)(2a)	4.00-5.30	9.00-11.45	11.00-13.30

Detailed agenda

¹ Some of these times are at antisocial hours for some of our international colleagues. We will endeavour to record sessions so that colleagues can view the presentations at a more convenient time.

buiten verzoek

9:05 - 10:20 **Session III: Influenza and COVID-19 co-circulation – experience from the Southern Hemisphere and subtropical climates**

Moderators:

- Measuring influenza VE during SARS-CoV-2 co-circulation – results, challenges and lessons learnt, 15 min (10)(2e)
- Measuring influenza VE during SARS-CoV-2 co-circulation – the experience from (10)(2a) 15 min (10)(2e)
- Influenza/ARI and COVID-19 cases in (10)(2a) and timing of social distancing measures: results from surveillance data, 15 min (10)(2e)
- Discussion, 30 min

Session IV: Influenza and COVID-19 co-circulation: challenges and plans at primary care level for (10)(2e) and beyond

28th of September, Monday; 14:00–16:15 CEST

14:00 - 14:05 **Welcome and introduction** (ECDC, Epiconcept)

14:05 - 15:05 **Session IV: Influenza and COVID-19 co-circulation: challenges and plans at primary care level for (10)(2e) and beyond**

Moderators:

- **Primary care: Adapting the influenza sentinel surveillance system to both COVID-19 surveillance and measuring influenza vaccine effectiveness**
 - The experience from (10)(2a) 10 min (10)(2e) (10)(2e)
 - The experience from (10)(2a) 10 min (10)(2e) (10)(2e)
 - The experience from (10)(2a) 10 min (10)(2e)
- Discussion, 30 min

15:05 – 15:15 Comfort break

15:15 – 16:15 **Session IV continued: Influenza and COVID-19 co-circulation: challenges and plans at primary care level for (10)(2e) and beyond**

Moderators:

- **Primary care sentinel system challenges and approaches for the 2020–21 season: burden on health-care systems, influenza vaccine supply, surveillance, adaptation of platforms to measure COVID-19 interventions**
 - Reflections from (10)(2a) 10 min (10)(2e)
 - Reflections from (10)(2a) 10 min (PHS team)
 - Reflections from the (10)(2a) 10 min (the (10)(2e) team)
- Discussion, 30 min

Session V: Influenza and COVID-19 co-circulation: challenges and plans at hospital level for (10)(2e) and beyond

29th of September, Tuesday; 14:00–16:05 CEST

14:00-14:05 **Welcome and introduction** (ECDC, Epiconcept)

14:05 - 15:05 **Session V: Influenza and COVID-19 co-circulation: challenges and plans at hospital level for (10)(2a) and beyond**

Moderators:

- **Hospital: Coping with COVID-19 surveillance and measuring 2019–20 influenza vaccine effectiveness**
 - Reflections from (10)(2a) 10 min (10)(2e) (10)(2e)
 - Reflections from (10)(2a), 10 min (10)(2e)
 - Reflections from (10)(2a) 10 min (10)(2e)
 - Discussion, 30 min
- 15:05 – 15:15 Comfort break
- 15:15 – 15:55 **Session V continued: SARI surveillance plans for the future**
- Moderators:
- **SARI surveillance and respiratory pathogen vaccine effectiveness in the WHO (10)(2a) region, WHO/Euro, 10 min (WHO/Euro team)**
 - TBC, 10 min, ()
 - Discussion, 20 min
- 15:55 – 16:05 Comfort break (note that session VI follows on directly after the break)

Session VI: Influenza vaccine and COVID-19

29th of September, Tuesday; 16:05–16:45 CEST

16:05 - 16:45 Session VI: Influenza vaccine and COVID-19

Moderators:

- Influenza vaccine does not increase the risk of coronavirus – results from (10)(2a) 10 min (10)(2e)
- Association between influenza vaccine and COVID-19 at primary care level – preliminary results from (10)(2a) 10 min (10)(2e)
- Discussion, 20 min

buiten verzoek